Mecillinam or a placebo was added to a combination of cefazolin and carbenicillin as an early therapy of septicemia caused by gram-negative organisms in patients with serious underlying diseases, none of whom was neutropenic, however. Patients in whom infection was caused by pathogens against which mecillinam and cefazolin or mecillinam and carbenicillin were synergistic might have responded more often than patients treated with nonsynergistic combinations. However, overall results did not show any benefit from combining mecillinam with cefazolin and carbenicillin. This study suggests that in nonneutropenic patients with septicemia caused by gram-negative organisms, there is no need to intensify antimicrobial therapy beyond a certain point of efficacy. The measurement of the bactericidal activity in the serum of treated patients might serve as guide for adequate therapy.
Bacteremia caused by gram-negative organisms (gram-negative bacteremia) remains a serious disease, especially in those patients whose natural defense against infection is diminished by a severe underlying disease. In neutropenic patients with gram-negative bacteremia, prompt empiric therapy with combinations of antibiotics has been shown to improve the outcome (3, 15) . It is likely that patients with severe underlying diseases such as cancer, even if not neutropenic, might benefit from such an approach. Various combinations of antibiotics have been used for empiric therapy of suspected sepsis in cancer patients (6) . Of these combinations, the association of carbenicillin with a cephalosporin has been investigated in several trials (2, 10, 14) ; it has been found to be usually active and well tolerated, but, in some studies, its efficacy was found to be lower than that of aminoglycosidecontaining combinations, which are frequently synergistic against pathogens responsible for gram-negative sepsis (5, 9) . Synergy, which can be demonstrated in vitro, is probably important for the outcome of infections caused by gramnegative rods (1, 7, 11) .
Mecillinam is a member of a new group of ,Blactam antibiotics, the amidinopenicillins, and has novel properties in terms of chemical structure, antibacterial spectrum, and mode of action. Mecillinam exhibits high in vitro activity against most members of the Enterobacteriaceae (18). Although it interferes with the biosynthesis of the bacterial cell wall like the penicillins and cephalosporins, mecillinam has a very specific mode of action, binding to only two of the penicillin-binding proteins in the inner membrane of Escherichia coli, which are believed to be involved in the cell wall metabolism of gram-negative organisms (16) . This distinct, yet related, activity may be responsible for the synergistic interaction which has been observed both in vitro (12) and in vivo (4, 13) The determination of the antimicrobial activity (back titration) of the serum against the pathogens isolated in this series was performed as described previously (8) .
Antibiotics were administered for up to 10 days, although they were stopped when a satisfactory re 10 9 Pulmonary infection 4 2 Soft tissue infections 3 4 and abscesses Biliary tract infection 1 0
Gastroenteritis 1 0 Indwelling catheter 1 3 Not established 9 10 a In addition to carbenicillin and cefazolin.
of the uncontrolled infection. In the other patient, the microorganism became resistant to both antibiotics during therapy and required a change of the antibiotics. A fourth patient had some response, and follow-up blood cultures were negative; that patient required surgery (colostomy), and antibiotics were changed at that time.
In addition, one patient in each group was infected with a resistant pathogen.
There were no obvious reasons for the clinical failure of therapy in three patients in the mecillinam-treated group and two patients in the control group. Responses in relation to susceptibility of pathogens, in vitro synergy, and serum titers. Table 4 Tables 5   TABLE 3 The bactericidal activity of serum, obtained 1 h after the administration of the antibiotics, was determined in 45 patients in this series. Only three had levels lower than 1/8, and two out of three responded well to therapy. All the other patients had bactericidal titers which exceeded 1/8. No difference could be found, as far as clinical or bacteriological outcome was concerned, between patients who had very high bactericidal titers (>1/128) and those with bactericidal titers of between 1/8 and 1/128.
Incidence of superinfection and colonization. Superinfection as a consequence of bacterial colonization of the site of infection during therapy was observed in three patients. All had been treated with active mecillinam in addition to cefazolin and carbenicillin. In one patient, superinfection was due to S. aureus susceptible only to cefazolin, and in the others, superinfec- (13) . In addition, synergy between antimicrobial agents has been shown to influence favorably the outcome of severe gram-negative bacillary infections, especially in compromised patients (1, 7) . This is the reason why we conducted this trial in patients with gram-negative bacteremia complicating a severe underlying disease, most often a disseminated malignancy.
Overall results of this randomized, doubleblind investigation did not show any advantage of adding mecillinam to cefazolin and carbenicillin; the success rate was 79% in the patients receiving cefazolin and carbenicillin and 69% in those treated with the same regimen plus mecillinam. When the clinical response was studied in relation to the susceptibility of the pathogens to the study antibiotics, it was found that the clinical response seemed to depend only on the fact that at least one of the antibiotics administered was active in vitro against the infecting organism.
The most likely explanation for the lack of a demonstrable advantage of mecillinam in this series is the efficacy of the control regimen (cefazolin and carbenicillin) used here. It resulted in a high rate of clinical responses (79%) and in high levels of antibacterial activities of the sera of treated patients. One might wonder whether much improvement is feasible under these circumstances. There was a trend in this series indicating that patients who were treated with synergistic combinations (mecillinam-cefazolin or mecillinam-carbenicillin) might have had a better response than patients receiving nonsynergistic combinations. This is in accorAance with previous studies from this laboratory (7, 11) and with those reported by Anderson et al. (1) . These investigators pointed out that the importance of in vitro synergy for the outcome of gram-negative sepsis was related to the severity of the impairment of the host's defenses, namely, to neutropenia. In our study, in patients with normal granulocyte counts, the response was similar whether the pathogen was susceptible to one, two, or three of the study drugs. Once again, this suggests that in nonneutropenic patients, therapy with cefazolin or carbenicillin at the dosage given here is adequate, provided the pathogen is susceptible at least to one of the antibiotics. As the data derived here from the study of the bactericidal activity of serum indicate, no improvement in the clinical outcome was associated with very high bactericidal titers. This is in accordance with previous studies in our hospital indicating that for optimal therapy of gram-negative bacillary infections the bactericidal titer of the serum obtained 1 h after the administration of antibiotics should be 1/8 (8) .
Thus, in nonneutropenic patients, adequate therapy of gram-negative infection can be realized easily with one drug therapy. The need for synergy or for very high levels of antimicrobial activity in the serum is not obvious. On the other hand, in neutropenic patients, therapy with multiple drug regimens is indicated not only to cover a large spectrum of possible pathogens before the microbial data become available, but also to take advantage of a possible synergistic action of the drugs against the pathogen (1, 3, 11, 15 (2, 3, 5) . In the large cooperative study conducted by the EORTC International Antimicrobial Project Group, a combination of carbenicillin and gentamicin was the optimal therapy; the combination of cephalothin and carbenicillin was suboptimal because strains resistant to both antibiotics were responsible for sepsis in some patients and because all these patients failed to respond (3). Whether mecillinam has a role as an adjunct to that type of therapy has not been studied.
